DK1225878T3 - RAR-gamma-selektive retinoidagonister til behandling af emfysem - Google Patents

RAR-gamma-selektive retinoidagonister til behandling af emfysem

Info

Publication number
DK1225878T3
DK1225878T3 DK00972754T DK00972754T DK1225878T3 DK 1225878 T3 DK1225878 T3 DK 1225878T3 DK 00972754 T DK00972754 T DK 00972754T DK 00972754 T DK00972754 T DK 00972754T DK 1225878 T3 DK1225878 T3 DK 1225878T3
Authority
DK
Denmark
Prior art keywords
rar
emphysema
treatment
retinoid agonists
selective retinoid
Prior art date
Application number
DK00972754T
Other languages
Danish (da)
English (en)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1225878T3 publication Critical patent/DK1225878T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00972754T 1999-10-19 2000-10-13 RAR-gamma-selektive retinoidagonister til behandling af emfysem DK1225878T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (1)

Publication Number Publication Date
DK1225878T3 true DK1225878T3 (da) 2007-03-05

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00972754T DK1225878T3 (da) 1999-10-19 2000-10-13 RAR-gamma-selektive retinoidagonister til behandling af emfysem

Country Status (34)

Country Link
US (1) US6300350B1 (hu)
EP (1) EP1225878B1 (hu)
JP (2) JP4074458B2 (hu)
KR (1) KR100485581B1 (hu)
CN (1) CN1201730C (hu)
AR (1) AR029648A1 (hu)
AT (1) ATE344661T1 (hu)
AU (1) AU777325B2 (hu)
BR (1) BR0015225A (hu)
CA (1) CA2387844C (hu)
CY (1) CY1105941T1 (hu)
CZ (1) CZ20021657A3 (hu)
DE (1) DE60031790T2 (hu)
DK (1) DK1225878T3 (hu)
ES (1) ES2274810T3 (hu)
HK (1) HK1051002A1 (hu)
HR (1) HRP20020329A2 (hu)
HU (1) HUP0203295A3 (hu)
IL (1) IL149151A0 (hu)
JO (1) JO2178B1 (hu)
MA (1) MA26835A1 (hu)
MX (1) MXPA02003843A (hu)
MY (1) MY129001A (hu)
NO (1) NO328738B1 (hu)
NZ (1) NZ518118A (hu)
PE (1) PE20010678A1 (hu)
PL (1) PL357499A1 (hu)
PT (1) PT1225878E (hu)
RS (1) RS50165B (hu)
RU (1) RU2257383C2 (hu)
TR (1) TR200201071T2 (hu)
TW (1) TWI288639B (hu)
WO (1) WO2001030326A1 (hu)
ZA (1) ZA200202576B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
EP1430024A1 (en) * 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
JP4410562B2 (ja) 2001-09-18 2010-02-03 エフ．ホフマン−ラ ロシュ アーゲー 置換尿素レチノイド作用薬ｉｉ
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
JP4926707B2 (ja) 2003-08-22 2012-05-09 ダニスコ エイ／エス 封入化抗菌材料
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
EP2613776B1 (en) 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
BR112013033309B1 (pt) 2011-06-24 2022-07-05 Gri Bio, Inc Uso de tazaroteno e método in vitro para inibição de ativação de células nkt tipo i
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
BR112015014349A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por hidratação mucosa insuficiente
EP3044216B1 (en) 2013-08-20 2022-02-23 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
JP3704471B2 (ja) * 1997-11-12 2005-10-12 エフ．ホフマン−ラ ロシュ アーゲー レチノイド拮抗薬を用いるヘルパーｔ細胞媒介性免疫疾患の処置
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
JP3961827B2 (ja) * 1999-08-02 2007-08-22 エフ．ホフマン−ラ ロシュ アーゲー 新規な選択的レチノイドアゴニスト
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
US6300350B1 (en) 2001-10-09
HUP0203295A3 (en) 2003-04-28
JO2178B1 (en) 2003-04-23
JP2007302689A (ja) 2007-11-22
BR0015225A (pt) 2002-07-16
YU29002A (sh) 2005-06-10
HK1051002A1 (en) 2003-07-18
EP1225878A1 (en) 2002-07-31
PE20010678A1 (es) 2001-07-04
TR200201071T2 (tr) 2002-08-21
ES2274810T3 (es) 2007-06-01
NO20021823L (no) 2002-04-18
IL149151A0 (en) 2002-11-10
DE60031790T2 (de) 2007-09-20
RU2257383C2 (ru) 2005-07-27
WO2001030326A1 (en) 2001-05-03
CA2387844A1 (en) 2001-05-03
KR100485581B1 (ko) 2005-04-27
PL357499A1 (en) 2004-07-26
CA2387844C (en) 2009-04-14
ATE344661T1 (de) 2006-11-15
NO20021823D0 (no) 2002-04-18
ZA200202576B (en) 2003-09-23
AR029648A1 (es) 2003-07-10
JP2003512418A (ja) 2003-04-02
RS50165B (sr) 2009-05-06
NO328738B1 (no) 2010-05-03
CN1201730C (zh) 2005-05-18
MA26835A1 (fr) 2004-12-20
JP4074458B2 (ja) 2008-04-09
MXPA02003843A (es) 2002-09-30
MY129001A (en) 2007-03-30
TWI288639B (en) 2007-10-21
JP4850791B2 (ja) 2012-01-11
AU777325B2 (en) 2004-10-14
PT1225878E (pt) 2007-01-31
AU1137401A (en) 2001-05-08
CN1382042A (zh) 2002-11-27
HRP20020329A2 (en) 2004-04-30
CY1105941T1 (el) 2011-04-06
EP1225878B1 (en) 2006-11-08
NZ518118A (en) 2004-02-27
HUP0203295A2 (hu) 2003-01-28
CZ20021657A3 (cs) 2002-10-16
KR20020043640A (ko) 2002-06-10
DE60031790D1 (de) 2006-12-21

Similar Documents

Publication Publication Date Title
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1772141T3 (da) Fremgangsmåde til gennemföring af krystallisation i fast tilstand
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DE60132651D1 (de) Positionsbestimmungssystem
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK2258688T3 (da) Pyridinon-derivater til behandling af aterosklerose
DK1225878T3 (da) RAR-gamma-selektive retinoidagonister til behandling af emfysem
DK1206436T3 (da) Retinoider til behandling af emfysem
DK1324970T3 (da) Retinoider til behandling af emfysem
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK199800837A (da) Anlæg til behandling af emner
DE60202537D1 (de) Torpedostartsystem
DE60130137D1 (de) Kristallisationsverfahren
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DE60214042D1 (de) Nass-trocken-reinigungssystem
DK0981950T3 (da) Fremgangsm,åde til formering af phyllocactus
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
FI20012516A (fi) Päänviennin menetelmä
DE10224030B4 (de) Spannsystem
ITPR980020A1 (it) Incorniciatura rapida
ITMO20010226A0 (it) Apparato
DE50200113D1 (de) Spannbare Schelle
DE60201909D1 (de) Zoom-verfahren
DK1140984T3 (da) Selektive inhibitorer af MMP-12